| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/11/2005 | CA2269783C Method for preparing malonate methylidene nanoparticles, nanoparticles optionally containing one or several biologically active molecules |
| 01/11/2005 | CA2269128C Piperazino derivatives as neurokinin antagonists |
| 01/11/2005 | CA2248235C Use of honey as an agent to reduce the adhesion of microorganisms |
| 01/11/2005 | CA2241244C Use of inhibitors of the activity of retinoic acid for treating sensitive skin and/or acute damage induced by uv radiation |
| 01/11/2005 | CA2215351C Process for isolating galanthamine |
| 01/11/2005 | CA2213719C Transparent rapid-release preparation of non-steroid analgesics |
| 01/11/2005 | CA2200068C A preparation for external use and a patch having the preparation attached thereto |
| 01/11/2005 | CA2193493C Thiazolidine derivatives for the treatment of psoriasis |
| 01/11/2005 | CA2169631C A novel homeobox factor which stimulates insulin expression in pancreatic islet cells |
| 01/11/2005 | CA2151443C Cycloheptimidazole derivatives, method of manufacturing the same and therapeutic agents containing these compounds |
| 01/11/2005 | CA2104909C Decahydroisoquinolines as excitatory amino acid receptor antagonists |
| 01/08/2005 | CA2469089A1 En-2 gene, disgnostic and therapeutic uses thereof |
| 01/06/2005 | WO2005002224A1 Circuit for processing video signal containing information such as closed caption |
| 01/06/2005 | WO2005001469A1 Method of acidic polysaccharide analysis and kit for the analysis |
| 01/06/2005 | WO2005001092A2 Compositions and methods for diagnosing and treating cancers |
| 01/06/2005 | WO2005001055A2 Stabilized immunomodulatory oligonucleotides |
| 01/06/2005 | WO2005001041A2 Compositions and methods for inhibiting an isoform of human manganese superoxide dismutase |
| 01/06/2005 | WO2005001040A2 Non-lethal conditioning methods for conditioning a recipient for bone marrow transplantation |
| 01/06/2005 | WO2005000906A1 Disialoundecasaccharide chain asparagine/fatty acid amide and medical drug containing the same |
| 01/06/2005 | WO2005000900A1 Treatment with anti-vegf antibodies |
| 01/06/2005 | WO2005000869A1 Neuroactive 13,24-cyclo-18,21-dinorcholanes and structurally-related pentacyclic steroids |
| 01/06/2005 | WO2005000865A1 Microbial method for hydrolysis and oxidation of androst-5-ene and pregn-5-ene steroid esters |
| 01/06/2005 | WO2005000850A2 Novel crystalline forms of valacyclovir hydrochloride |
| 01/06/2005 | WO2005000846A1 Hexahydropyridoisoqinolines as dpp-iv inhibitors |
| 01/06/2005 | WO2005000845A2 Bicyclic derivatives as nk-1 and nk-2 antagonists |
| 01/06/2005 | WO2005000842A1 Benzothiazole derivatives as adenosine receptor ligands |
| 01/06/2005 | WO2005000838A1 4-(aminomethyl)-piperidine benzamides as 5ht4-antagonists |
| 01/06/2005 | WO2005000837A1 Aminosulfonyl substituted 4-(aminomethyl)-piperidine benzamides as 5ht4-antagonists |
| 01/06/2005 | WO2005000836A1 Substituted indazolyl(indolyl)maleimide derivatives as kinase inhibitors |
| 01/06/2005 | WO2005000833A1 Immunosuppressant compounds and compositions |
| 01/06/2005 | WO2005000831A1 ESTERS OF FLAVONOIDS WITH ω-SUBSTITUTED C6-C22 FATTY ACIDS |
| 01/06/2005 | WO2005000830A1 Pharmaceutical compositions comprising cabbinochreme type compounds |
| 01/06/2005 | WO2005000829A1 Cannabinoid receptor modulator |
| 01/06/2005 | WO2005000819A1 Process for the preparation of nonpeptide substituted spirobenzoazepine derivatives |
| 01/06/2005 | WO2005000809A1 Substituted 3-alkyl and 3-alkenyl azetidine derivatives |
| 01/06/2005 | WO2005000806A2 Ligands for nicotinic acetylcholine receptors, and methods of making and using them |
| 01/06/2005 | WO2005000795A2 Aniline derivatived androgen-, glucocorticoid-, mineralcorticoid- and progesterone- receptor modulators |
| 01/06/2005 | WO2005000789A1 2-amino-3-alkoxybicyclo[3.1.0]hexane derivative |
| 01/06/2005 | WO2005000786A1 Sertraline compositions |
| 01/06/2005 | WO2005000778A1 Hsp90 FAMILY PROTEIN INHIBITORS |
| 01/06/2005 | WO2005000406A2 Treatment of amyloid- and epileptogenesis-associated diseases |
| 01/06/2005 | WO2005000405A2 P38 kinase inhibitor compositions and methods of use |
| 01/06/2005 | WO2005000404A2 Heterocyclic compounds for preventing and treating disorders associated with excessive bone loss |
| 01/06/2005 | WO2005000402A2 Anti-adhesion composites and methods os use thereof |
| 01/06/2005 | WO2005000361A1 Menthol-containing preparation |
| 01/06/2005 | WO2005000357A2 Chemical combination and method for increasing delivery of coenzyme q 10 |
| 01/06/2005 | WO2005000356A1 Remedy for urinary tract diseases |
| 01/06/2005 | WO2005000353A1 Serum cholesterol lowering agnet or preventive or therapeutic agent for atherosclerosis |
| 01/06/2005 | WO2005000340A1 Synergistic compositions comprising erythropoietin and succinic acid (salt) |
| 01/06/2005 | WO2005000334A1 Abuse resistant amphetamine compounds |
| 01/06/2005 | WO2005000333A1 Methods to mobilize progenitor/stem cells |
| 01/06/2005 | WO2005000331A2 Compositions for the treatment and prevention of degenerative joint disorders |
| 01/06/2005 | WO2005000330A1 Angiogenic agents from plant extracts, gallic acid, and derivatives |
| 01/06/2005 | WO2005000329A1 Composition and method for treating upper abdominal pain and cramping |
| 01/06/2005 | WO2005000325A2 Composition for treating and/or preventing dysfunctions associated with type 2 diabetes mellitus |
| 01/06/2005 | WO2005000321A1 Use of hyaluronic acid for preparing compositions for treating oral cavity aphthas |
| 01/06/2005 | WO2005000320A2 Use of double-stranded ribonucleic acid for inducing cell lysis |
| 01/06/2005 | WO2005000319A1 Composition for external use |
| 01/06/2005 | WO2005000318A2 Method of inducing apoptosis and inhibiting cardiolipin synthesis |
| 01/06/2005 | WO2005000317A1 Enhancement of activity and/or duration of action of soft anti-inflammatory steroids for topical or other local application |
| 01/06/2005 | WO2005000316A1 External preparation for improving coital function |
| 01/06/2005 | WO2005000315A1 Combination product comprising an antagonist or inverse agonist of histamine receptor h3 and an antipsychotic or antidepressant agent, and use thereof for the preparation of a medicament that prevents the adverse effects of psychotropic drugs |
| 01/06/2005 | WO2005000314A1 Method for treating diseases using hsp90-inhibiting agents in combination with antimitotics |
| 01/06/2005 | WO2005000313A1 Antiepileptic agent |
| 01/06/2005 | WO2005000312A1 Sustained drug-relase particles and process for producing the same |
| 01/06/2005 | WO2005000311A1 Substituted diketopiperazines for the treatment of benign prostatic hyperplasia |
| 01/06/2005 | WO2005000310A1 Multiparticulates |
| 01/06/2005 | WO2005000309A2 Chemical compounds |
| 01/06/2005 | WO2005000308A2 Methods of identifying hcv ns5b polymerase inhibitors and use against hepatitis c |
| 01/06/2005 | WO2005000307A1 Ophthalmic composition containing quinolones and method of use |
| 01/06/2005 | WO2005000306A1 Flupirtine preparation for treating neurodegenerative disorders of the visual system and diabetes mellitus |
| 01/06/2005 | WO2005000304A1 Pyrazolo[3,4-b]pyridin-6-ones as gsk-3 inhibitors |
| 01/06/2005 | WO2005000303A1 Pyrazolo`3,4-b!pyridin-6-ones as gsk-3 inhibitors |
| 01/06/2005 | WO2005000302A1 Use of pyrazolopyridines for the treatment of cognitive deficits |
| 01/06/2005 | WO2005000300A1 Substituted 5-membered ring compounds and their use |
| 01/06/2005 | WO2005000299A1 Compositions comprising balaglitazone and further antidiabetic compounds |
| 01/06/2005 | WO2005000297A1 Treatment of migraine accompanied by nausea |
| 01/06/2005 | WO2005000296A1 Pharmaceutical solid dosage forms exhibiting reproductible drug release profile |
| 01/06/2005 | WO2005000295A1 Rage antagonists as agents to reverse amyloidosis and diseases associated therewith |
| 01/06/2005 | WO2005000294A1 Selective inhibitor and an anticonvulsant agent for the treatment of central nervous system disorders |
| 01/06/2005 | WO2005000292A1 Cancer treatment with epothilones |
| 01/06/2005 | WO2005000291A1 Method for treatment of idiopathic pulmonary fibrosis using triptolide derivatives |
| 01/06/2005 | WO2005000290A1 Ibuprofen-containing film-coated tablet |
| 01/06/2005 | WO2005000289A1 Topical use of valproic acid for the prevention or treatment of skin disorders |
| 01/06/2005 | WO2005000288A2 Treatment of protein aggregation disorders |
| 01/06/2005 | WO2005000287A1 External preparation for athlete's foot treatment |
| 01/06/2005 | WO2005000286A1 Composition for relieving or lessening fatigue and medical device fitted with the composition |
| 01/06/2005 | WO2005000285A2 METHODS OF TREATING NON-INFLAMMATORY GASTROINTESTINAL TRACT DISORDERS USING Cav2.2 SUBUNIT CALCIUM CHANNEL MODULATORS |
| 01/06/2005 | WO2005000284A2 Diaryl ureas for diseases mediated by pdgfr |
| 01/06/2005 | WO2005000283A2 A method of treating degenerative disc disease |
| 01/06/2005 | WO2005000282A2 Inhibitors of histone deacetylases for the suppression therapy of diseases |
| 01/06/2005 | WO2005000276A1 Tablet comprising fluvastatin and carmellose calcium |
| 01/06/2005 | WO2005000270A2 Inhalable formulations for treating pulmonary hypertension and methods of using same |
| 01/06/2005 | WO2005000269A1 Pharmaceutical formulations comprising a proton pump inhibitor |
| 01/06/2005 | WO2005000268A2 Bioerodible sustained release drug delivery systems |
| 01/06/2005 | WO2005000267A2 Spray drying of an alcoholic aqueous solution for the manufacture of a water-insoluble active agentmicroparticle with a partial or complete amino acid and/or phospholipid coat |
| 01/06/2005 | WO2005000265A2 Gel-stabilized nanoparticulate active agent compositions |
| 01/06/2005 | WO2005000250A2 Imaging agents and methods of imaging alpha 7-nicotinic cholinergic receptor |
| 01/06/2005 | WO2005000248A2 Compositions and methods for skin conditioning |
| 01/06/2005 | WO2005000247A2 4-carboxamido quinoline derivatives for use as nk-2 and nk-3 |